The text starts here.

News Release

February 14, 2006
For Print (PDF 103KB)

FDA Accepts Eisai's sNDA Application for Aricept(R) In the Treatment of Severe Alzheimer's Disease

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO Haruo Naito) announced today that the FDA (U.S. Food and Drug Administration) has accepted a supplemental New Drug Application (sNDA) for Aricept(R) (donepezil HCl tablet) for the treatment of severe Alzheimer's Disease on February 13, 2006. Eisai Medical Research Inc. (Headquarters: New Jersey, President: Mindell Seidlin), a U.S. subsidiary of Eisai Co., Ltd. submitted the revised application on December 16, 2005.

Corporate Communications Department
Eisai Co., Ltd.
TEL: 81-3-3817-5120